Self-Assessment Answers for Section 1: Evidence-Based Guidance on Responsible Prescribing, Effective Management, and Harm Reduction
1 . In the United States, approximately how many non-medical users of pain relievers, tranquilizers, stimulants, and sedatives got their prescription drugs from a friend or relative for free? 2 . What two competing needs must the CSA and regulators attempt to balance? 3 . Which attribute of some drugs with legitimate therapeutic uses increases their likelihood of being abused? 4 . The duration of action of ER/LA opioids is typically ______________. 5 . Uncomfortable or unpleasant side effects (aside from constipation) may potentially be reduced by which two approaches? 6 . What drug class has largely replaced barbiturates as treatment for anxiety and muscle spasms? 7 . Which of the following items does not need to be contained in any prescription for a controlled substance? 8 . Which of the following might suggest inappropriate prescribing of controlled substances by a clinician? 9 . The Ryan Haight Act made it illegal to _____________. 10 . Which of the following is not a potential benefit of urine drug screening? 11 . Drugs with the highest risk for subsequent addiction slowly elicit dopamine release in the midbrain. 12 . Although initially thought to be less prone to induce tolerance and dependence than barbiturates, benzodiazepines are now recognized to be just as liable to diversion and abuse. 13 . Little evidence supports the assertion that long-term use of opioids provides clinically significant pain relief or improves quality of life or functioning. 14 . Roughly what percent of patients reported that they increased their dose of an opioid without talking to the prescribing physician in one study? 15 . When opioid treatment is initiated, it should be viewed by both patient and clinician as _____________________? 16 . Opioid tolerance must be demonstrated before prescribing any strength of _________________. 17 . What level of opioid dose is widely considered a red flag warranting more intense monitoring and/or referral to an interdisciplinary treatment team? 18 . What relatively new development may reduce the incidence of death from accidental overdose of an opioid medication? 19 . For patients at the end of life, optimal pain management may mean lower doses of an analgesic, and higher levels of pain, in order to allow the patient mental alertness sufficient for interactions with loved ones. 20 . Medication-Assisted Treatment is primarily used for treating
Self-Assessment Answers for Section 2: Prescriber Education for Opioid Analgesics
21 . When evaluating patients for treatment with extended-release/long-acting (ER/LA) opioid analgesics, which is an important risk to consider? 22 . Which of the following is true of methadone? 23 . Nonpharmacologic therapies for pain treatment 24 . For which of the following pain conditions are ER/LA opioids indicated? 25 . According to assessment tools, which of the following factors heighten risk for opioid-use disorder? 26 . Name 1 method by which patients should be encouraged to dispose of unused opioids 27 . Name 1 way patients should be monitored for adherence to medical direction during long-term opioid therapy? 28 . Which of the following is true of potential drug-drug interactions with opioids? 29 . In which of the following clinical scenarios may a patient be discontinued from opioids without taper and management of withdrawal symptoms? 30 . Which of the following is 1 indication for take-home naloxone with opioid prescription? 31 . Increased monitoring of patient response is essential during opioid dose initiation, upward titration, rotation, and addition of other central-nervous system depressants because 32 . Urine drug testing as a monitoring measure can tell the clinician which of the following: 33 . Which of the following factors increases a patient’s risk of opioid misuse? 34 . Recommended frequency to check the prescription drug-monitoring database is: 35 . Which of the following influences the amount of dopamine released and the degree of reward experienced by an opioid user?